These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23432690)

  • 21. Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer.
    Zhang LY; Li PL; Wang TZ; Zhang XC
    Arch Gynecol Obstet; 2015 Oct; 292(4):891-7. PubMed ID: 25827305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome.
    Calvo X; Nomdedeu M; Navarro A; Tejero R; Costa D; Muñoz C; Pereira A; Peña O; Risueño RM; Monzó M; Esteve J; Nomdedeu B
    Leuk Res; 2014 Aug; 38(8):874-81. PubMed ID: 24880536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis.
    Mahfoudhi E; Talhaoui I; Cabagnols X; Della Valle V; Secardin L; Rameau P; Bernard OA; Ishchenko AA; Abbes S; Vainchenker W; Saparbaev M; Plo I
    DNA Repair (Amst); 2016 Jul; 43():78-88. PubMed ID: 27289557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXXC4 mRNA levels are associated with clinicopathological parameters and survival of myelodysplastic syndrome patients.
    Li S; Fan R; Zhao XL; Wang XQ
    Leuk Res; 2014 Sep; 38(9):1072-8. PubMed ID: 25085016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
    Soura EN; Karikas GA
    J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
    Santamaría C; Ramos F; Puig N; Barragán E; de Paz R; Pedro C; Insunza A; Tormo M; Del Cañizo C; Diez-Campelo M; Xicoy B; Salido E; Sánchez del Real J; Hernández M; Chillón C; Sanz GF; García-Sanz R; San Miguel JF; González M
    Ann Hematol; 2012 Dec; 91(12):1887-95. PubMed ID: 22875062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential expression of ten-eleven translocation genes in endometrial cancers.
    Ciesielski P; Jóźwiak P; Wójcik-Krowiranda K; Forma E; Cwonda Ł; Szczepaniec S; Bieńkiewicz A; Bryś M; Krześlak A
    Tumour Biol; 2017 Mar; 39(3):1010428317695017. PubMed ID: 28349832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH2 regulates U2AF1 expression and hydroxymethylation in MDS patients.
    Cheng H; Liu Y; Cheng M; Li W; Sun M; Tang Q; Ma J; Li P; Gong T
    Biotechnol Genet Eng Rev; 2024 Oct; 40(2):788-799. PubMed ID: 36942631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.
    Takayama K; Misawa A; Suzuki T; Takagi K; Hayashizaki Y; Fujimura T; Homma Y; Takahashi S; Urano T; Inoue S
    Nat Commun; 2015 Sep; 6():8219. PubMed ID: 26404510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins.
    Pirola CJ; Scian R; Gianotti TF; Dopazo H; Rohr C; Martino JS; Castaño GO; Sookoian S
    Medicine (Baltimore); 2015 Sep; 94(36):e1480. PubMed ID: 26356709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1.
    Liu C; Liu L; Chen X; Shen J; Shan J; Xu Y; Yang Z; Wu L; Xia F; Bie P; Cui Y; Bian XW; Qian C
    PLoS One; 2013; 8(5):e62828. PubMed ID: 23671639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
    Wang J; Ai X; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Hu N; Zhang Y; Xiao Z
    Leuk Res; 2013 Mar; 37(3):305-11. PubMed ID: 23099237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation.
    Kudo Y; Tateishi K; Yamamoto K; Yamamoto S; Asaoka Y; Ijichi H; Nagae G; Yoshida H; Aburatani H; Koike K
    Cancer Sci; 2012 Apr; 103(4):670-6. PubMed ID: 22320381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.
    Feng Y; Liang H; Han M; Luo X; Zhu Y; Liu B
    Hematology; 2023 Dec; 28(1):2220222. PubMed ID: 37288803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
    Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
    Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.